Associated Papers
A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors.
Siu LL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
40875525 (PubMed )
Supplement: ccr-25-1648_supplementary_table_s5_suppts5.xlsx › Sheet1
Comprehensive Analysis of Human Colorectal Cancers Harboring Polymerase Epsilon Mutations.
Gibson LM et al.
International Journal of Molecular Sciences, 2025
40806338 (PubMed )
Supplement: ijms-26-07208-s001.zip › Table_S2.xlsx › Colorectal_CHASM_p-values
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
Ambrosini M et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2024
Scrutinizing Deleterious Nonsynonymous SNPs and Their Effect on Human POLD1 Gene.
Bappy MNI et al.
Genetics Research, 2022
DNA polymerase delta Exo domain stabilizes mononucleotide microsatellites in human cells.
Shioi S et al.
Dna Repair, 2021
The POLD1R689W variant increases the sensitivity of colorectal cancer cells to ATR and CHK1 inhibitors.
Job A et al.
Scientific Reports, 2020
Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase δ mutation in human cells.
Mertz TM et al.
Oncogene, 2017
Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy.
Barbari SR et al.
Dna Repair, 2017
POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies.
Nicolas E et al.
Gene, 2016
Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer.
Yoshida R et al.
European Journal of Human Genetics : Ejhg, 2011
Select a paper to view details